Introduction {#Sec1}
============

Retinoic acid receptor-related orphan receptor (ROR) alpha is a member of the nuclear hormone receptor (NR) superfamily. NRs function as ligand-dependent DNA binding factors that translate hormonal, nutritional and pathophysiological signals into gene regulation. In the context of metabolism, NRs control lipid and glucose homeostasis in an organ- or tissue-specific manner \[[@CR1]--[@CR4]\]. It has been demonstrated that liver x receptor agonists and oxygenated sterols function as RORα/γ ligands that can suppress receptor activity \[[@CR5]\].

Several studies on RORα \[[@CR2]--[@CR4], [@CR6], [@CR7]\] have revealed a role for this NR in fatty acid homeostasis \[[@CR8]\]. Homozygous staggerer (*sg*/*sg*) mice, which have a global *Rorα* (also known as *Rora*) defect, display decreased and dysfunctional RORα (1 and 4) levels in all tissues \[[@CR7], [@CR9]--[@CR11]\]. Moreover, *sg/sg* mice have a lean and dyslipidaemic phenotype, and are similar to *Rorα*-deficient mice (*sg* operates as a non-functional null allele) \[[@CR12]\]. These mice display hypoalphalipoproteinaemia, decreased serum triacylglycerol and HDL-cholesterol \[[@CR3]\], vulnerability to atherosclerosis \[[@CR3]\], decreased fat depots and resistance to diet-induced obesity \[[@CR9]\].

Dysfunctional NR signalling has been associated with dyslipidaemia, insulin resistance, diabetes and obesity \[[@CR6], [@CR7]\]. For example, the dietary lipid-dependent NRs (peroxisome proliferator-activated receptor-gamma, liver x receptor alpha etc.) in skeletal muscle regulate insulin-stimulated glucose disposal, and lipid and energy homeostasis \[[@CR13]--[@CR15]\]. Muscle is a major mass tissue that accounts for around 40% of the total body mass and energy expenditure, and is a major site of glucose disposal. Hence muscle has an important role in regulating insulin sensitivity and is increasingly recognised as an important target for combating type 2 diabetes.

Type 2 diabetes is a complex metabolic disease characterised by glucose intolerance and insulin resistance, which result in decreased insulin-mediated glucose utilisation in peripheral tissues \[[@CR16]\]. In this context, investigation of the role of the orphan NR, RORα, in the regulation of glucose metabolism has not been completely analysed in the literature. Accordingly, we surveyed the functional role of RORα in glucose tolerance and insulin sensitivity, with particular attention to skeletal muscle.

We observed that homozygous (*sg*/*sg)* and heterozygous (*sg*/+) mice exhibited mildly improved glucose tolerance and increased insulin sensitivity. Expression profiling identified perturbations in the v-AKT murine thymoma viral oncogene homologue (AKT) signalling cascade and in genes involved in the control of glucose homeostasis. For example, we observed enhanced (absolute) levels of: (1) *Akt2* mRNA in the basal state; and (2) phosphorylated AKT (pAKT) (in the basal and insulin stimulated states); and (3) (ex vivo) glucose uptake in skeletal muscle from *sg/sg* mice relative to wild-type littermates. In summary, RORα plays an important role in regulation of the AKT signalling cascade.

Methods {#Sec2}
=======

**Animals** Heterozygous *sg*/+ mice, B6.C3(Cg)-*Rora*^*sg*^/J, were obtained from Jackson laboratory (Bar Harbor, ME, USA) and maintained by backcrossing to C57BL/6 J. Feeding has been described previously \[[@CR9]\]. Male wild-type and homozygous (*sg/sg*) mice were fed with a normal diet until 14 weeks and fasted for 6 h by transferring to a food-free holding cage with access to water. Animals were killed and tissues collected and immediately frozen in liquid nitrogen. All animal procedures were approved by The University of Queensland Animal Ethics Committee.

**Glucose tolerance test** Blood glucose measurements were obtained from the tail vein of 12 h fasted animals (14--16 weeks old) following glucose challenge, using a blood glucose testing system (Accu-chek Performa; Roche Diagnostics, Castle Hill, NSW, Australia) \[[@CR17]\].

**Insulin tolerance test and insulin stimulation of AKT phosphorylation** Blood glucose measurements were obtained from 6 h fasted animals (14--16 weeks old) following insulin challenge, as previously described \[[@CR17]\]. For measurement of skeletal muscle pAKT, 6 h fasted mice were administered insulin or saline as described for insulin tolerance test, killed by CO~2~ asphyxiation after 10 min and quadriceps muscle excised and snap-frozen.

**Microarray analysis** Microarray and statistical analysis were as previously described \[[@CR17]\] except that GeneSpring GX v7.3.1 (Agilent, Santa Clara, CA, USA) was used for analysis.

**RNA extraction, cDNA synthesis and quantitative PCR** Total RNA extraction, cDNA synthesis and quantitative PCR were performed as previously described \[[@CR2], [@CR9]\]. Primers are listed in the Electronic supplementary material (ESM) Table [1](#MOESM1){ref-type=""}.

**Protein extraction and western blot analysis** Protein extraction and western analysis was performed as previously described \[[@CR17]\] with the following modifications. The lysis buffer contained 50 mmol/l Tris (pH 8.0), 150 mmol/l NaCl, 1% (vol./vol.) Triton X-100, 1% (wt/vol.) NP40 and 0.1% (wt/vol.) SDS, and tissue was centrifuged at 2,000×*g*. Membranes were blocked with either 5% (wt/vol.) dried skimmed milk or 5% (wt/vol.) BSA (for phospho-specific antibodies). The anti-GLUT4 (number 62375; Abcam, Cambridge, MA, USA) antibody was used at 1:5,000.

**2-Deoxy-[d]{.smallcaps}-glucose uptake assay** Extensor digitorum longus (EDL) muscles were dissected from mice (3--7 months old) following cervical dislocation and 2-deoxy-[d]{.smallcaps}-glucose uptake assay was performed with or without 10 nmol/l insulin stimulation (Actrapid; Nova Nordisk, Baulkham Hills, NSW, Australia) as previously described \[[@CR18], [@CR19]\].

**Indirect calorimetry** Respiratory exchange ratio (RER) was measured using a monitoring system (Oxymax Comprehensive Lab Animal System; Columbus Instruments, Columbus, OH, USA). Mice were housed individually in metabolic cages on a 12 h day--night cycle. Following an initial 14 h acclimatisation period, measurements were taken every 10 min for 24 h on normal diet (D12450B; Research Diets, New Brunswick, NJ, USA). After 24 h measurement, food was then withdrawn and measurements were taken for a further 6 h.

**Statistical analysis** Results were analysed by unpaired *t* test or one-way ANOVA with Bonferroni's post-hoc test, or by two-way ANOVA with Bonferroni's post hoc test; Prism 5 software (GraphPad, San Diego, CA, USA) was used.

Results {#Sec3}
=======

**Staggerer mice present decreased fasting glucose levels, improved glucose tolerance and increased insulin sensitivity** We have previously demonstrated that homozygous staggerer *(sg/sg*) mice (with decreased and dysfunctional RORα levels) display a lean phenotype. Here, we used *sg/sg* mice to elucidate the role of RORα in glucose tolerance and insulin sensitivity. We examined male wild-type and homozygous *sg/sg* mice fed a normal diet until 14 weeks and observed significantly lower blood glucose levels in homozygous *sg/sg* than in wild-type mice (*n* = 7--11) after 6 and 12 h of fasting (Fig. [1a, b](#Fig1){ref-type="fig"}). Plasma insulin levels in the *sg/sg*, relative to wild-type mice were also decreased (but did not attain significance, *p* = 0.08) (Fig. [1c](#Fig1){ref-type="fig"}). We further examined systemic glucose metabolism and performed intraperitoneal glucose tolerance tests. In the *sg/sg* mice, glucose clearance was mildly improved following a glucose challenge (Fig. [1d, e](#Fig1){ref-type="fig"}), with no significant differences in insulin secretion after 10 min (data not shown). The *sg/sg* mice also displayed significantly enhanced responsiveness to administration of intraperitoneal insulin, indicating enhanced whole-body insulin action compared with wild-type mice (Fig. [1f, g](#Fig1){ref-type="fig"}). Fig. 1**a** Starting blood glucose levels of 6 h fasted male homozygous *sg/sg* (black column)*,* heterozygous *sg/+* (het) (striped column) and wild-type (white column) mice. These mice were used for insulin tolerance test (**f, g**); *n* = 5--9 per group, mean ± SEM; \*\**p* \< 0.01 by one-way ANOVA with Bonferroni's post hoc test. **b** Starting blood glucose levels of 12 h fasted mouse groups as above (**a**). These mice were used for GTT (**d, e**); *n* = 6--11 per group, mean ± SEM; \*\**p* \< 0.01 by one-way ANOVA with Bonferroni's post hoc test. **c** Plasma insulin concentrations of 12 h fasted male *sg/sg* wild-type littermate control mice on a regular chow diet; *n* = 4 per group, mean ± SEM. **d, e** Glucose tolerance tests. Blood glucose concentrations were measured at various times (**d**) after i.p. administration of glucose (*t* = 0) to 12 h fasted male *sg/sg* (black squares)*, sg/+* (het) (circles) and wild-type (Wt) (white squares) littermate control mice; *n* = 6--11 per group, mean ± SEM; \**p* \< 0.05 by two-way ANOVA with Bonferroni's post hoc test. **e** Mean AUC from glucose tolerance test; mean ± SEM; \**p* \< 0.05 by one-way ANOVA with Bonferroni's post hoc test. **f, g** Insulin tolerance tests. Blood glucose concentrations were measured and expressed as percentage of starting glucose (*t* = 0) at various times (**f**) after i.p. administration of insulin (*t* = 0) to 6 h fasted male *sg/sg* (black squares)*, sg/+* (het) (circles) and wild-type littermate control (white squares) mice; *n* = 5--9 per group, mean ± SEM; \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001 by two-way ANOVA with Bonferroni's post hoc test. **g** Mean AUC from insulin tolerance test; mean ± SEM; \**p* \< 0.05, \*\**p* \< 0.01 by one-way ANOVA with Bonferroni's post-hoc testHomozygous *sg/sg* mice are characteristically lean. They display decreased adipose mass and body weight \[[@CR9]\]. In contrast, the size:weight ratio of heterozygote (*sg*/+, haploinsufficient) mice is comparable to that of their wild-type counterparts (ESM Fig. [1](#MOESM2){ref-type=""}a, b). The heterozygous *sg/+* mice provided a tool to investigate whether the improvement in insulin sensitivity observed in *sg/sg* mice involved differential adiposity. Therefore we investigated whether glucose clearance and/or insulin sensitivity were altered in *sg*/+ mice. We observed significant improvement in glucose tolerance and insulin sensitivity compared with wild-type mice (Fig. [1d](#Fig1){ref-type="fig"}--[g](#Fig1){ref-type="fig"}), indicating that the increased insulin sensitivity was independent of the animal's degree of adiposity (and weight).We also explored whether the improvement in insulin sensitivity involved a shift to (more insulin-sensitive) type I/slow fibres and/or oxidative type IIa/x fibres. Accordingly, we examined the four myosin heavy chain genes, *Myh1*, *-2*, *-4* and *-7* (in wild-type and *sg/sg* mice), which identify and classify types I, IIa, IIb and IIx fibres, respectively (ESM Fig. [2](#MOESM3){ref-type=""}a--d). In addition, we also examined mRNA expression of the genes encoding type I and II troponin I\'s (*Tnni1*, *Tnni2*) (ESM Fig. [2](#MOESM3){ref-type=""}e, f). There were no significant shifts in the mRNA expression of genes encoding any of these fibre type markers. This suggests that improved insulin sensitivity was independent of transitions in muscle fibre types.Whole-body metabolic analysis indicated that RER in wild-type and *sg/sg* mice was similar (in the fed or dark, and fasted phases), suggesting that these lines use fats and carbohydrates for energy to a similar degree in the dark and light phases (Fig. [2a, b](#Fig2){ref-type="fig"}). The *sg/sg* mice are characteristically lean \[[@CR9]\] and resistant to diet-induced obesity \[[@CR9]\]. We also showed (ESM Fig. [1](#MOESM2){ref-type=""}c, d) that on the regular chow diet the wild-type and *sg/sg* littermates ate similar quantities of food. O~2~ consumption in the *sg/sg* relative to wild-type mice was significantly increased. These observations are consistent with previous reports that demonstrated a 30 to 70% higher metabolic rate (depending on temperature) and higher endogenous levels of norepinephrine in (cold-reared) *sg/sg* mice relative to control mice \[[@CR20]\], and increased *β*~*2-*~*AR* (also known as *Adrb2*) mRNA expression in brown adipose tissue from *sg/sg* mice \[[@CR9]\]. In summary, the *sg/sg* mice displayed mildly improved glucose tolerance and increased insulin sensitivity. Fig. 2CLAMS Oxymax metabolic monitoring of *sg/sg* (black circles and columns) and wild-type littermate control (white circles and columns) mice. **a** RER measurement over 12 h (day) and 12 h (night) with food and 6 h fasting. **b** Mean ± SEM for RER measurement in specified phases (**a**). *n* = 8--11 per group

**Expression profiling of skeletal muscle from sg/sg mice identified differential expression of genes involved in AKT signalling, and in cardiovascular and metabolic disease** To probe the mechanisms underlying improved insulin sensitivity, we performed expression profiling analysis using BeadArray chips (46 K; Illumina Sentrix; Illumina, San Diego, CA, USA). Muscle (quadriceps) RNA from three male *sg/sg* mice and their wild-type littermates was utilised for analysis. Statistically significant differential up- and downregulation of annotated genes was determined on the basis of a *p* value cut-off of *p* \< 0.05 and a fold change cut-off of 1.2 as shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively (for the complete list, see ESM Fig. [3a](#MOESM4){ref-type=""}, [b](#MOESM5){ref-type=""}, [c](#MOESM6){ref-type=""}). All differentially expressed genes were analysed using Ingenuity Pathway Analysis ([www.ingenuity.com](http://www.ingenuity.com)) to examine their putative function and associated signalling pathways. Table 1Upregulated annotated genes in *sg/sg* miceGene symbolGene nameGenbank IDFold change*p* value*Plekhh1*Pleckstrin homology domain containing, family H (with Myth4 domain) member 1XM_126961.41.970.002*Cidea*Cell death-inducing DNA fragmentation factor, alpha subunit-like effector aNM_007702.11.690.039*Dnase1*Deoxyribonuclease 1NM_010061.21.640.005*Ddit4*DNA-damage-inducible transcript 4NM_029083.11.570.018*Synj2*Synaptojanin 2AK0380381.560.008*Tph1*Tryptophan hydroxylase 1NM_009414.11.500.003*Cdkn1a*Cyclin-dependent kinase inhibitor 1a (p21)NM_007669.21.490.026*Egln3*EGL nine homologue 3AK0335091.490.044*Gng2*Guanine nucleotide binding protein (G protein), gamma 2 subunitNM_010315.21.480.000*Klk1b26*Kallikrein 1-related petidase b26NM_010644.21.440.012*Akt2*Thymoma viral proto-oncogene 2NM_007434.21.440.036*Tns3*Tensin-3NM_0010835871.440.027*Mt2*Metallothionein 2NM_008630.11.430.024*Igh-1a*Immunoglobulin heavy chain 1aXM_354704.11.430.044*Bcl2*B cell leukaemia/lymphoma 2NM_009741.21.430.016*Chrna9*Cholinergic receptor, nicotinic, alpha polypeptide 9XM_132045.21.400.030*Snrk*SNF related kinaseNM_133741.11.400.050*Acot11*Acyl-CoA thioesterase 11NM_025590.41.390.033*Slc25a25*Solute carrier family 25, member 25NM_146118.21.390.040*Syt12*Synaptotagmin 12NM_134164.21.380.009*Foxo1*Forkhead box o1NM_019739.21.370.040*Cdkn1a*Cyclin-dependent kinase inhibitor 1a (p21)NM_007669.21.360.035*Tsc22d1*TSC22 domain family, member 1NM_009366.31.360.015*Tsc22d3*TSC22 domain family, member 3NM_010286.21.360.013*Igfbp3*Insulin-like growth factor binding protein 3NM_008343.11.350.015*Notch4*Notch gene homologue 4 (Drosophila)NM_010929.11.340.010*Car2*Carbonic anhydrase 2NM_009801.31.340.005*Mt3*Metallothionein 3NM_013603.11.320.002*Tbrg4*Transforming growth factor beta regulated gene 4NM_134011.11.320.043*Tbc1d1*TBC1 domain family, member 1NM_019636.11.310.004*Map3k6*Mitogen-activated protein kinase 6NM_0166931.310.046*Sox13*SRY-box containing gene 13NM_011439.11.310.016*Shcbp1*Shc SH2-domain binding protein 1NM_011369.11.300.033*Lmcd1*LIMand cysteine-rich domains 1NM_144799.11.290.009*Syn2*Synapsin IINM_013681.11.290.017*Ercc5*Excision repair cross-complementing rodent repair deficiency, complementation group 5NM_011729.11.290.040*Syt3*Synaptotagmin 3NM_016663.21.290.035*Car4*Carbonic anhydrase 4NM_007607.11.280.003*Fgfr2*Fibroblast growth factor receptor 2, transcript variant 1NM_010207.11.280.013*Dlk1*Delta-like 1 homologue (Drosophila)NM_010052.11.270.005*Itga10*Integrin, alpha 10XM_1121921.270.026*Klk1b26*Kallikrein 1-related petidase b26NM_010644.21.260.013*Plin3*Perilipin 3NM_025836.31.260.004*Prom1*Prominin 1NM_008935.11.260.002*Zbtb32*Zinc finger and BTB domain containing 32NM_021397.21.260.041*Sh3bp2*SH3-domain binding protein 2NM_0118931.260.012*Car14*Carbonic anhydrase 14NM_011797.11.250.001*Olfr420*Olfactory receptor 420NM_146305.11.250.033*Fkbp5*FK506 binding protein 5NM_010220.21.250.029*Lao1*l-amino acid oxidase 1NM_133892.31.250.017Table 2Downregulated annotated genes in *sg/sg* miceGene symbolGene nameGenbank IDFold change*p* value*Cpeb2*Cytoplasmic polyadenylation element binding protein 2NM_175937−1.790.007*Opn1mw*Opsin 1 (cone pigments), medium-wave-sensitive (colour blindness, deutan)NM_008106.1−1.700.026*Stab2*Stabilin 2NM_138673.1−1.690.000*Sfrp2*Secreted frizzled-related sequence protein 2NM_009144.1−1.650.025*Col7a1*Procollagen, type VII, alpha 1NM_007738.1−1.640.001*Pla2g7*Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)NM_013737.2−1.520.006*Hspa1a*Heat shock protein 1aNM_010479−1.500.034*Cadm1*Cell adhesion molecule 1, transcript variant 3NM_018770.3−1.500.011*Cadm1*Cell adhesion molecule 1, transcript variant 3NM_018770.3−1.500.026*Cldn10*Claudin 10, transcript variant 2NM_021386−1.470.011*Cited4*Cbp/P300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4NM_019563−1.450.046*Pogk*Pogo transposable element with KRAB domainNM_175170−1.450.007*Tiam1*T cell lymphoma invasion and metastasis 1NM_009384.1−1.440.002*Ptx3*Pentaxin related geneNM_008987.2−1.380.042*Phex*Phosphate regulating gene with homologies to endopeptidases on the X chromosomeNM_011077.1−1.370.046*Ifitm6*Interferon induced transmembrane protein 6XM_133956.3−1.360.036*Gne*GlucosamineNM_015828−1.360.015*Fbn1*Fibrillin 1AK080935−1.340.020*Pon1*Paraoxonase 1NM_011134.1−1.340.020*Exph5*Exophilin 5NM_176846.3−1.340.021*Rasd2*RASD family, member 2XM_204287.3−1.330.005*Adamts1*A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1NM_009621−1.330.026*Timd4*T cell immunoglobulin and mucin domain containing 4NM_178759.3−1.330.032*Cd209d*CD209 antigen-like protein dNM_130904.2−1.330.027*Neto2*Neuropilin (NRP) and tolloid (TLL)-like 2XM_134498−1.330.050*Tekt1*Tektin 1NM_011569.1−1.330.002*Retnlg*Resistin like gammaNM_181596.2−1.320.047*Avil*AdvillinNM_009635.2−1.320.003*Fgf10*Fibroblast growth factor 10NM_008002.3−1.310.036*Hist1h4b*Histone 1, H4bNM_178193−1.310.016*Jph2*Junctophilin 2NM_021566.1−1.300.042*Arhgap20*Rho Gtpase activating protein 20NM_175535−1.300.017*Fancl*Fanconi anaemia, complementation group lNM_025923.2−1.300.027*Cyhr1*Cysteine and histidine rich 1NM_019396−1.300.037*Tinag*Tubulointerstitial nephritis antigenNM_012033.2−1.300.017*Dguok*Deoxyguanosine kinaseAK003639−1.290.005*Rora*Rar-related orphan receptor alphaNM_013646.1−1.290.018*Stat1*Signal transducer and activator of transcription 1BC057690.1−1.290.026*Csf-1*Colony stimulating factor 1X05010−1.280.047*Ubtf*Upstream binding transcription factor, RNA polymerase iNM_011551−1.280.020*Atxn7l2*Ataxin 7 like protein 2NM_175183.2−1.270.023*Arhgap20*Rho Gtpase activating protein 20NM_175535−1.270.038*Cd209a*CD209a antigenNM_133238.2−1.270.023*Aqp9*Aquaporin 9NM_022026.2−1.260.009*Dpysl3*Dihydropyrimidinase-like 3NM_009468.1−1.260.021*Enpp2*Ectonucleotide pyrophosphatase/phosphodiesterase 2NM_015744−1.260.000*Ache*AcetylcholinesteraseNM_009599.2−1.260.016*Cul9*Cullin 9NM_001081335−1.260.039*Ube2d1*Ubiquitin-conjugating enzyme E2D 1, UBC4/5 homologue (yeast)NM_145420.1−1.260.027*Astn2*Astrotactin 2, transcript variant 1NM_207109.1−1.260.049The phosphatidylinositol 3-kinase (PI3K)--AKT signalling pathway was the primary pathway to be upregulated (ESM Fig. [4c](#MOESM7){ref-type=""}) in *sg/sg* mice. We focused on the PI3K--AKT pathway to better understand the role of RORα (and the effect of RORα deficiency) on skeletal muscle carbohydrate metabolism. Importantly, using Ingenuity Pathway Analysis, this pathway also had the highest ranking association with genes that are significantly upregulated in bead-array (Illumina) analysis. For example, the PI3K--AKT pathway had the highest ratio (4.4 × 10^−2^), i.e. calculation of the number of genes in a pathway that are differentially expressed (in a significant manner) divided by the total number of known genes in that pathway. Second, it displayed a very significant *p* value (1.1 × 10^−4^), i.e. confidence of the association between the pathway and the differentially expressed genes.This is consistent with a phenotype displaying improved insulin sensitivity. The majority of differentially expressed genes were associated with metabolic disease, diabetes, dyslipidaemia and obesity (ESM Fig. [5](#MOESM8){ref-type=""}).

**Akt2 expression is increased in staggerer (sg/sg) mice** The Ingenuity analysis identified PI3K--AKT signalling as the most significantly increased pathway. In the context of further elucidating the mechanisms involved in the control of glucose tolerance in the skeletal muscle of *sg/sg* mice, we used quantitative PCR to validate the differential expression of mRNAs encoding *Akt* in skeletal muscle, liver and adipose tissue of male *sg/sg* mice relative to wild-type littermates (see Fig. [3a--l](#Fig3){ref-type="fig"}). Fig. 3Quantitative PCR of *Akt1*, *Akt2* (variant \[var\] 1 and var 2) and *Akt3* mRNA in (**a--d**) quadriceps muscle, (**e--h**) liver and (**i--l**) epididymal adipose tissue of male *sg/sg* mice (black columns) relative to wild-type littermates (white columns). *n* = 7--8 per group, \*\*\**p* \< 0.001 by *t* test. **m** Schematic representation of genomic structure of *Akt2* var 1 and *Akt2* var 2, and use of alternative promoter. Excerpt from MGI mouse genome browser at website as cited \[[@CR45]\]. **n--p** Quantitative PCR of *Akt1, Akt2* var1 and *Ak2* var 2 mRNA in quadriceps muscle of male wild-type (white columns), heterozygous *sg/+* (striped columns) and homozygous *sg/sg* mice (black columns) (3--7 months old). *n* = 10--12 per group, \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001 by one-way ANOVA with Bonferroni's post hoc test. All bar graph values mean ± SEM, with relative mRNA expression normalised against 18S rRNAWe observed significantly increased levels of *Akt1* and *Akt2* (variant 2) mRNA, but not of *Akt3* mRNA in muscle from (fasted) *sg/sg* mice (Fig. [3a--d](#Fig3){ref-type="fig"}). Interestingly, two variants of *Akt2* have been described in the NCBI database (ncbi.nlm.nih.gov/nucleotide, accessed 17 December 2010). Variants 1 and 2 are produced by alternate promoter usage and result in exon 1 encoding different 5′ untranslated region sequences (Fig. [3m](#Fig3){ref-type="fig"}). Variant 2, but not variant 1, mRNA was increased in staggerer mice (Fig. [3b, c](#Fig3){ref-type="fig"}). Notably, no significant changes in *Akt1*, *Akt2* (variants 1 and 2) or *Akt3* mRNA expression were observed in liver or adipose tissue (Fig. [3e--i](#Fig3){ref-type="fig"}).Levels of *Rorα* mRNA in the muscle of heterozygous staggerer mice are approximately half of those in wild-type mice (ESM Fig. [1](#MOESM2){ref-type=""}b). To understand further the effect of *Rorα* expression on transcription of *Akt* isoforms, we analysed the expression of *Akt1*, *Akt2* variant 1 and *Akt2* variant 2 mRNAs in the heterozygote (RORα haplo-insufficient mice). The expression of *Akt2* variant 2 (but not variant 1) mRNA in quadriceps muscle in heterozygous mice was intermediate between wild-type and homozygous staggerer (*sg/sg*) mice (Fig. [3o, p](#Fig3){ref-type="fig"}). In contrast *Akt1* mRNA expression was similar to that of wild-type mice (Fig. [3n](#Fig3){ref-type="fig"}).We also determined by western blot analysis whether changes in mRNA expression correlated with changes in the protein levels of total AKT (Fig. [4a](#Fig4){ref-type="fig"}) and phosphorylated (serine amino acid residue 473 \[ser473\]) AKT (Fig. [4b](#Fig4){ref-type="fig"}) in quadriceps muscle of wild-type and *sg/sg* mice in the basal (unstimulated) state. We observed a significant increase in total AKT protein (normalised against glyceraldehyde-3-phosphate dehydrogenase \[GAPDH\] protein) in the skeletal muscle from *sg/sg* mice relative to wild-type littermate pairs (Fig. [4a](#Fig4){ref-type="fig"}), corresponding with the mRNA expression data. In addition, levels of the active phosphorylated (ser473) AKT species was also significantly increased (normalised against GAPDH) (Fig. [4b](#Fig4){ref-type="fig"}) in the basal condition. Fig. 4Western blot analyses of (**a)** AKT and (**b)** pAKT relative to GAPDH in skeletal muscle (quadriceps) of male *sg/sg* and wild-type (WT) littermate control mice, with densitometry analysis of western blots; *n* = 4 per group, mean ± SEM; \**p* \< 0.05 and \*\*\**p* \< 0.001 by *t* test. **c** Western blot analyses (representative blot from two experiments) of AKT and (**d)** pAKT relative to GAPDH in skeletal muscle (quadriceps) of male wild-type (Wt) and *sg/sg* littermate mice treated with saline and insulin (0.5 U/kg i.p. for 10 min). Densitometry was analysed using both experiments; *n* = 4--6 per group, mean ± SEM; \**p* \< 0.05 and \*\**p* \< 0.01 two-way ANOVA with Bonferroni's post hoc test

**Aberrant expression in sg/sg mice of genes involved in regulation of glucose tolerance and metabolic disease** The nodes of the insulin signalling pathway (underscoring the central role of AKT2) are summarised in Fig. [5a](#Fig5){ref-type="fig"}. We used quantitative PCR to analyse mRNA expression of the *p85α* (also known as *Pik3r1*) and *p85β* (also known as *Pik3r2*) regulatory subunits of PI3K. However, no significant differences in expression were observed in the muscle of male *sg/sg* mice (Fig. [5b, c](#Fig5){ref-type="fig"}). Fig. 5**a** Schematic representation of the insulin-mediated glucose disposal pathway in skeletal muscle. InsR, insulin receptor. **b--i** Quantitative PCR of mRNA from skeletal muscle (quadriceps) of male *sg/sg* (black columns) mice relative to wild-type (Wt) littermates (white columns) for genes as labelled. Relative mRNA expression was normalised against 18S rRNA; *n* = 7--8 per group, mean ± SEM; \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001, by *t* test. **j** Western blot analyses of GLUT4 in skeletal muscle (quadriceps) from male *sg/sg* and wild-type (WT) littermate control mice, with densitometry analysis (grey, *sg/sg*; white, wild-type littermate control) using both western blots; *n* = 8--9 per group, mean ± SEM; \**p* \< 0.05 by *t* testWe also validated the differential expression of *Tbc1d1* (which encodes a Rab GTPase-activating protein, and the paralogue *Tbc1d4* \[also known as *As160*\]) and several other genes in the *sg/sg* mice (relative to wild-type littermates). These genes have been implicated in AKT signalling and the regulation of glucose tolerance and/or insulin sensitivity. For example, TBC1D1 has recently been identified (as an AKT substrate) in the insulin-stimulated AKT cascade that facilitates GLUT4 translocation \[[@CR21]\] and regulates glucose uptake \[[@CR22]\]. The *Tbc1d1* and *Tbc1d4* mRNA were significantly induced (about threefold) and decreased, respectively (Fig. [5d, e](#Fig5){ref-type="fig"}) in *sg/sg* mice. Serum- and glucocorticoid-inducible kinase 1 (*Sgk1*) was similarly induced by about threefold (Fig. [5f](#Fig5){ref-type="fig"}). Serum- and glucocorticoid-inducible kinase 1 modulates salt-dependent glucose uptake and mediates several PI3K responses, with emerging evidence suggesting it interacts with AKT kinases and mammalian transducer of regulated cAMP response element-binding protein 2 \[[@CR23]\]. Polymorphisms (and increases) of paraoxonase 1 are associated with glucose intolerance and type 2 diabetes, and, consistent with the phenotype, was decreased by about twofold (Fig. [5g](#Fig5){ref-type="fig"}). Finally, *Tip47* (also known as *Plin3)* in skeletal muscle has been shown to maintain insulin sensitivity \[[@CR24]--[@CR26]\]; its mRNA was significantly induced by about 2.5-fold (Fig. [5h](#Fig5){ref-type="fig"}).With regard to glucose transporters, we observed no changes in expression of *Glut1* (also known as *Slc2a1*) mRNA (data not shown); however, we did observe a small but significant increase in *Glut4* (also known as *Slc2a4*) mRNA expression (Fig. [5i](#Fig5){ref-type="fig"}). The increase in *Glut4* mRNA was reflected in a significant, approximately twofold increase in the level of GLUT4 protein after western blot analysis of *sg/sg* mice, relative to wild-type littermates (*n* = 9; Fig. [5j](#Fig5){ref-type="fig"}).The differential expression of these genes in muscle of *sg/sg* mice was consistent with improved insulin sensitivity, and with increased AKT levels and AKT phosphorylation. These analyses thus revealed that several components of the insulin signalling pathway are modulated in the *sg/sg* phenotype, these modulations being associated with decreased blood glucose and improved insulin signalling.

**Staggerer mice display significantly elevated \'absolute levels\' of pAKT and total AKT protein in the basal and insulin-stimulated states, and have enhanced ex vivo glucose uptake** We subsequently examined whether *sg/sg* mice display increased insulin-mediated AKT phosphorylation. Whole-cell extracts from quadriceps muscles were isolated from saline- and insulin-injected mice were analysed by western blot analysis using antibodies specific to AKT and pAKT. We observed significantly elevated \'absolute levels\' of total AKT protein (in the basal and insulin-stimulated states) in quadriceps muscle from *sg/sg* mice (normalised against GAPDH) (Fig. [4c](#Fig4){ref-type="fig"}). We also observed significantly elevated \'absolute levels\' of insulin-stimulated phosphorylation of AKT (ser473) in *sg/sg* mice (normalised against GAPDH) (Fig. [4d](#Fig4){ref-type="fig"}).We next investigated whether the improved insulin sensitivity and elevated \'absolute\' levels of AKT and pAKT in *sg/sg* mice resulted in increased ex-vivo glucose uptake in EDL muscle (type II fast twitch glycolytic muscle) (Fig. [6](#Fig6){ref-type="fig"}). In keeping with the increase in AKT level and phosphorylation, EDL muscle of *sg/sg* mice showed significantly higher rates of 2-deoxy-[d]{.smallcaps}-glucose uptake than wild-type mice in the basal and insulin-stimulated state. Fig. 62-Deoxy-[d]{.smallcaps}-**\[**^3^H\]glucose uptake assays of control and insulin-treated EDL muscle explants from male wild-type (Wt) and *sg/sg* mice (3--7 months old); *n* = 7--10 per group, mean ± SEM; \**p* \< 0.05 and \*\**p* \< 0.01 By two-way ANOVA with Bonferroni's post hoc test

Discussion {#Sec4}
==========

A recent review \[[@CR8]\] underscored the diverse roles of RORs in development, immunity, circadian rhythm, lipid homeostasis and metabolism. Moreover, (dysfunctional) levels of this NR are associated with ataxia, autoimmune disease, dyslipidaemia, atherosclerosis and resistance to diet-induced obesity. The *sg/sg* mice are *Rorα-*deficient, *sg/sg* is a non-functional null allele and *sg/sg* mice do not express functional RORα \[[@CR12]\]. Moreover, *sg/sg* mice display identical phenotypes to the *Rorα*-knockout mice, which do not produce RORα protein \[[@CR12], [@CR27]\].

The pathophysiological phenotypes in *sg/sg* mice are consistent with changes in the expression of genes such as *Srebp-1c* (also known as *Srebf1*), *Apoa1*, *Apoc3* and *IκBα* (also known as *Nfkbia*) \[[@CR4], [@CR7], [@CR9], [@CR28]\]. We have previously shown that *sg/sg* mice have significantly reduced *Rorα1* and *Rorα4* expression \[[@CR9]\], and display increased expression of Lipin 1 and *Pgc-1α* (also known as *Ppargc1a*), and decreased expression of *Srebp-1c*. The differential expression of these genes is consistent with the ability of *sg/sg* mice to resist diet-induced obesity and hepatic triacylglycerol accumulation \[[@CR9]\].

To date, the role of RORα in the control of insulin sensitivity and glucose uptake remains obscure. The links and interactions between fatty acid and carbohydrate homeostasis in whole-body physiology, and in the pathophysiological development of glucose intolerance and insulin resistance underscore the need to examine the role of this NR in carbohydrate metabolism. Consequently, we examined the outcomes of aberrant RORα function in muscle, a tissue that accounts for the bulk of insulin-stimulated glucose disposal \[[@CR29]\]. The (male) *sg/sg* mice present with significantly reduced fasting serum glucose and improved insulin sensitivity relative to wild-type littermates. Our results differ from those of Kang et al. who showed a lack of serum glucose phenotype in *sg/sg* compared with their wild-type mice \[[@CR30]\]. The nature of this difference is still not known. Recently it has been suggested that, in mice, a 6 h fast provides a more physiologically relevant baseline, increased sensitivity and fewer confounding variables for the evaluation of serum glucose and glucose tolerance \[[@CR31], [@CR32]\].

Expression profiling identified differential regulation of genes in the skeletal muscle of *sg/sg* mice. Similarly, bi-directional changes in gene expression have been observed in liver of *sg/sg* mice \[[@CR30]\]. In the analysis reported here, the upregulated subset of genes was associated with cardiovascular and metabolic disease, cell death, infection, immunity and inflammation. This is consistent with the defined role of RORα in atherosclerosis, lipid homeostasis, fat deposition, obesity and inflammation \[[@CR8], [@CR33]\]. Interestingly, the primary signalling pathway upregulated in muscle was the PI3K--AKT pathway, a central control point for insulin-stimulated glucose uptake. Two RNA variants of *Akt2* have been identified. We showed that *Akt2* variant 2 was highly expressed in epididymal fat and (quadricep) skeletal muscle, but not in liver of wild-type mice. We observed significant differential expression of *Akt1* and *Akt2* variant 2 in quadriceps of *sg/sg* mice, indicating a specific role for these signalling molecules in skeletal muscle.

Interestingly, we had previously demonstrated that transgenic muscle-specific overexpression of dominant-negative RORα1 leads to decreased *Akt2* mRNA expression, glucose intolerance, decreased insulin-stimulated phosphorylation of AKT and glucose uptake \[[@CR17]\]. In this study, we observed that decreased (and dysfunctional) expression of *Rorα* (*1* and *4*) led to increased *Akt2* mRNA expression and improved insulin sensitivity, and increased levels of basal and insulin-stimulated phosphorylation of AKT and of glucose uptake.

Notably in this context, the staggerer strain has a deletion of the fifth exon encoding the ligand binding domain. The resulting frame shift encodes \'non-sense RNA\' and introduces a premature stop codon. However, further analysis by northern blot \[[@CR34]\] and RT-PCR \[[@CR9]\] revealed greater than tenfold decreases in *Rorα1* and *Rorα4* mRNA expression. Moreover, northern blot analysis \[[@CR12]\] was not able to detect the transcript in homozygous *sg/sg* mice. Gold et al. \[[@CR34]\] state that this is consistent with 'degradation of the mutant mRNA through the non-sense mediated decay pathway'. In agreement with this, *sg/sg* mice do not produce the RORα protein. Although initially thought to have a dominant-negative form of RORα, *sg/sg* mice are in fact *Rorα-*deficient. In contrast to this, our previous study \[[@CR17]\] used a construct that abundantly/ectopically expresses a stable truncated *Rorα* mRNA transcript with an in-frame stop codon. The truncated *Rorα* ∆DE includes the encoded amino acids 1--235 \[[@CR17]\], but lacks the ligand binding domain and part of the hinge region. McBroom et al. \[[@CR35]\] and Lau et al. \[[@CR2]\] reported that deletion of this segment preserved DNA recognition and binding, suppressed transactivation and operated in a dominant-negative manner. In addition, Hamilton et al. \[[@CR11]\] reported that the staggerer mutation is located in a similar position and produces a non-functional ligand binding domain.

This apparent paradox in ROR function has a precedence in the NR field and there are a number of factors to consider. In the first instance, our previous transgenic mouse model overexpressed a dominant-negative *Rorα1* transcript, specifically in skeletal muscle \[[@CR17]\]. In comparison, the present study investigated *sg/sg* mice, which lack *Rorα1* and *Rorα4* expression in all tissues. Second, in mice lacking NR, 'bona fide' target genes are often derepressed, resulting in paradoxically increased expression \[[@CR36]\]. We suggest the data are consistent with decreased (and dysfunctional) RORα expression leading to derepression and increase of *Akt2* mRNA expression. This is consistent with our observation that RORα is selectively recruited to the *Akt2* promoter and that dominant-negative overexpression represses *Akt2* mRNA expression \[[@CR17]\]. More importantly, these studies clearly identify a link between *Rorα* expression, *Akt2* and glucose tolerance.

Previous studies \[[@CR37], [@CR38]\] have demonstrated transcriptional regulation of *Rev-erbα* (also known as *Nr1d1*) by RORα and decreased *Rev-erbα* mRNA expression in *sg/sg* mice \[[@CR37]\]. However, this did not explain the increased expression of *Akt2* mRNA in the *sg/sg* mice. For example, we also observe decreased expression of *Rev-erbα* in *sg/sg* mice; however, there was no decrease in REV-ERBα protein (ESM Fig. [6](#MOESM9){ref-type=""}). This is consistent with another report \[[@CR39]\], which showed 'dissociation between mRNA and protein levels'.

In the context of improved insulin sensitivity, glucose uptake and increased AKT levels, we also observed increased *Tbc1d1* and *Glut4* expression. This is entirely consistent with Peck and colleagues \[[@CR21]\], who very recently showed that activated AKT phosphorylates TBC1 domain family, member 1 (TBC1D1) and enhances glucose uptake. We also used quantitative PCR to validate the differential expression of several other mRNAs, including *Pon1* and *Sgk1*, that are associated with type 2 diabetes, insulin secretion and metabolic syndrome \[[@CR40], [@CR41]\] and also appeared in several categories, similarly to *Akt2*.

We were particularly interested in AKT2, as this protein is an integral component of the signalling pathway controlling insulin signalling. For example, several investigations have reported that AKT2 is a major regulator of insulin-mediated glucose disposal in skeletal muscle. Aberrant *Akt2* gene expression in rodents is associated with insulin resistance, type 2 diabetes-like syndrome, age-dependent lipodystrophy \[[@CR42], [@CR43]\] and phosphorylation of TBC1D1.

The threefold increase in expression of *Tbc1d1* mRNA, initially appears paradoxical. Mutations in *Tbc1d1* are associated with morbid obesity, for example, the R125W mutation in humans. However, the functional outcomes of these mutations have not yet been characterised. In the context of improved insulin sensitivity, glucose uptake and increased AKT level (and phosphorylation), we also observed increased *Tbc1d1* and *Glut4* expression. These observations are consistent with the latest studies on *Tbc1d1* function. Peck and colleagues recently demonstrated that AKT phosphorylation of TBC1D1 (similar to AKT substrate, 160 kDa/TBC1 domain family, member 4) enables GLUT4 translocation \[[@CR21]\]. Second, the obesity-related mutant R125W *Tbc1d1* decreases insulin-stimulated glucose transport \[[@CR22]\]. Both groups suggest that impaired glucose uptake provides a potential mechanism for the associated obesity. The differential (and increased) production of this Rab GTPase-activating protein, coupled to increased pAKT level in *sg/sg* mice, is interesting from the perspective of a potential contribution to resistance to diet-induced obesity in *sg/sg* mice via increased glucose uptake.

Interestingly, and consistent with increased insulin sensitivity, *sg/sg* mice showed enhanced insulin-mediated AKT phosphorylation and glucose uptake (and increased GLUT4 protein levels) in skeletal muscle. Recently, Duez et al. \[[@CR44]\] showed that overexpression of *Rorα4* in 3T3-L1 cells inhibits pre-adipocyte differentiation, *Glut4* transcription and insulin-induced glucose uptake. In agreement with this, we have shown here that the GLUT4 protein level was increased in muscle from *sg/sg* mice.

In conclusion, the NR, RORα*,* is involved in regulation of AKT production and signalling, and glucose uptake. This study extends previous evidence that RORα performs a critical role in the regulation of adiposity. Further studies are required to examine whether this NR can be therapeutically exploited.
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###### 

List of quantitative PCR primers (PDF 107 kb)

###### 

**a** Body weight (g) of 15-week-old fed male wild-type (wt; white column), heterozygous *sg/+* (striped column) and homozygous *sg/sg* (black column) mice; *n* = 5--6 per group, mean ± SEM; \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001 by one-way ANOVA with Bonferroni's post hoc test. **b** Quantitative PCR of wild-type *Rorα* (primers specific for wild-type *Rorα* mRNA only), *Rorα1* (primers detect wild-type and *sg Rorα1* mRNA isoforms) and *Rorα4* (primers detect wild-type and *sg Rorα4* mRNA isoforms) mRNA in quadriceps muscle of male *sg/sg* (black columns), heterozygous *sg/+* (striped columns) and wild-type (white columns) mice; *n* = 10--12 per group, 3 to 7 months old, mean ± SEM; \*\*\**p* \< 0.001 by one-way ANOVA with Bonferroni's post-hoc test. **c** CLAMS measurements of mean food intake during day (12 h) and night (12 h) by wild-type (white columns) and *sg/sg* (black columns) mice; *n* = 8--11 per group, mean ± SEM. **d** Oxygen consumption (VO2) during day (12 h), night (12 h) and fasting (6 h) by wild-type (white circles) and *sg/sg* (black circles) mice, with bar chart showing mean *V*O~2~ during day, night and fasting of wild-type (white column) and *sg/sg* (black column) mice; *n* = 8--11 per group, mean ± SEM; \*\**p* \< 0.01 by two-way ANOVA with Bonferroni's post hoc test (PDF 43 kb)

###### 

Quantitative PCR of (**a--d)** myosin heavy chain mRNA as labelled from quadriceps muscle of male wild-type (white columns) and homozygous *sg/sg* (black columns) mice, *n* = 10--12 per group, 3--7 months old, mean ± SEM. **e***Tnni1* and *Tnni2* (**f**) in quadriceps muscle of wild-type (white columns) and *sg/sg* (black columns) mice; *n* = 7--8 per group, mean ± SEM. Relative mRNA expression was normalised against 18S rRNA (PDF 644 kb)

ESM Fig. 3.

All up- and downregulated genes in

sg/sg

. Differentially expressed genes from the Illumina BeadArray analysis comparing

sg/sg

with wild-type mice. All genes had significant difference in expression above 1.24-fold. The fold change value presented is relative to wild-type mice

###### 

PDF 2,338 kb
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PDF 2,414 kb

###### 

PDF 1,890 kb

###### 

Ingenuity pathway analysis of differentially expressed genes. Differentially expressed genes from the Illumina BeadArray analysis comparing *sg/sg* with wild-type mice were analysed via Ingenuity pathway analysis to reveal the top ten: **(a)** functions associated with upregulated genes; (**b)** functions associated with downregulated genes; (**c)** pathways associated with upregulated genes; and (**d)** pathways associated with upregulated genes. *p* values represent Fisher\'s exact test with the threshold at *p* \< 0.05 (PDF 1.01 mb)

###### 

Functional annotation of genes that were up- or downregulated in *sg/sg* mice and associated with metabolic disorders. Differentially expressed genes from the Illumina BeadArray analysis comparing *sg/sg* to wild-type mice were analysed via Ingenuity pathway analysis. Differentially expressed genes with known associations to metabolic disorders are shown. Up arrows, upregulation; down arrows, downregulation (PDF 69 kb)

###### 

**a** Quantitative PCR of *Rev-erbα* mRNA in quadriceps muscle of wild-type (white column) and *sg/sg* (black column) mice; *n* = 7--8 per group, mean ± SEM; \*\**p* \< 0.01 by *t* test. **b** Western blot of REV-ERBα (Affinity BioReagents, Golden, CO, USA, diluted 1:1000; antibody not commercially available) in quadriceps muscle of wild-type (WT) and *sg/sg* mice (PDF 331 kb)
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